Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL)
cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).